ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Arch Therapeutics Inc (QB)

Arch Therapeutics Inc (QB) (ARTH)

0.213473
0.00
(0.00%)
Closed December 02 3:00PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.213473
Bid
0.15
Ask
0.50
Volume
22
0.00 Day's Range 0.00
0.1701 52 Week Range 18.00
Market Cap
Previous Close
0.213473
Open
-
Last Trade
22
@
0.2499
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
10,781
Shares Outstanding
4,444,364
Dividend Yield
-
PE Ratio
-0.13
Earnings Per Share (EPS)
-1.57
Revenue
76k
Net Profit
-6.98M

About Arch Therapeutics Inc (QB)

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform wit... Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch's products authorized for commercial marketing are AC5 Advanced Wound System and AC5 Topical Hemostat. Arch's development stage product candidates include AC5-GTM and AC5 Surgical Hemostat, among others. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Carson City, Nevada, USA
Founded
-
Arch Therapeutics Inc (QB) is listed in the Surgical,med Instr,apparatus sector of the OTCMarkets with ticker ARTH. The last closing price for Arch Therapeutics (QB) was US$0.21. Over the last year, Arch Therapeutics (QB) shares have traded in a share price range of US$ 0.1701 to US$ 18.00.

Arch Therapeutics (QB) currently has 4,444,364 shares outstanding. The market capitalization of Arch Therapeutics (QB) is US$948,751.72 . Arch Therapeutics (QB) has a price to earnings ratio (PE ratio) of -0.13.

ARTH Latest News

Insider Financial Publishes New Research On Three Promising Biotechs

Insider Financial, a leading research site for microcap companies, publishes new research on Arch Therapeutics Inc (OTCBB:ARTH), Medifirst Solutions Inc (OTCMKTS:MFST), and Cellceutix Corp...

One Step Vending Corp. KOSK – 230% Growth and Over 150,000 Units Supplied

Miami, FL--(InvestorsHub NewsWire –July 14, 2016) - EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the...

Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at European Summit for Clinical Nanomedicine & Targeted Medicine ...

Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at European Summit for Clinical Nanomedicine and Targeted Medicine in Basel, Switzerland on June 23 WELLESLEY, MA--(Marketwired...

Arch Therapeutics Inc. to Present at the LD MICRO Invitational 2014 on June 4th

Arch Therapeutics Inc. to Present at the LD MICRO Invitational 2014 on June 4th WELLESLEY, MA--(Marketwired - May 28, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company...

Arch Therapeutics Inc. to Present at the Third Annual Marcum MicroCap Conference

Arch Therapeutics Inc. to Present at the Third Annual Marcum MicroCap Conference WELLESLEY, MA--(Marketwired - May 27, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company...

Arch Therapeutics Appoints Chirag Shah, PhD as Vice President of R&D Engineering & Quality Systems & Peter LaCrosse as Chief ...

Arch Therapeutics Appoints Chirag Shah, PhD as Vice President of R&D Engineering and Quality Systems and Peter LaCrosse as Chief of Staff Decades of Experience Adds Strength to Arch's...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.0134736.73650.20.2134730.220100.20487582CS
4-0.081927-27.73425863240.29540.350.268800.26780702CS
12-0.286527-57.30540.50.840.172107810.38394261CS
26-0.911527-81.02462222221.1251.20.170165480.47483038CS
52-3.706527-94.55426020413.92180.170195104.09637483CS
156-17.476527-98.793256076917.6927.40.170112089810.27793531CS
260-51.786527-99.58947552590.170122279723.5049067CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
EVOLSymbolic Logic Inc (CE)
US$ 0.99
(98,999,900.00%)
600
CRMBQCrumbs Bake Shop Inc (CE)
US$ 0.012
(1,199,900.00%)
15.64k
GPDBGreen PolkaDot Box Incorporated (CE)
US$ 0.0002
(19,900.00%)
21.54k
FCGDFirst Colombia Gold Corporation (PK)
US$ 0.0001
(9,900.00%)
600k
BIIOBionovate Technologies Corporation (CE)
US$ 0.0001
(9,900.00%)
1.21k
TIHETaihe Group Inc (CE)
US$ 0.000001
(-100.00%)
1
SBBGSeibels Bruce Group Inc (CE)
US$ 0.000001
(-100.00%)
4
MXLGFMX Gold Corporation (CE)
US$ 0.000001
(-100.00%)
1.1k
VIVEViveve Medical Inc (CE)
US$ 0.000001
(-99.75%)
652
SMGISMG Industries Inc (CE)
US$ 0.000001
(-99.50%)
10k
AITXArtificial Intelligence Technology Solutions Inc (PK)
US$ 0.00275
(0.00%)
51.06M
GTEHGenTech Holdings Inc (CE)
US$ 0.000001
(0.00%)
48.25M
HMBLHUMBL Inc (PK)
US$ 0.0002
(-33.33%)
42.65M
CBGLCannabis Global Inc (PK)
US$ 0.00015
(50.00%)
41.81M
GTVHGolden Triangle Ventures Inc (PK)
US$ 0.0008
(33.33%)
41.61M

ARTH Discussion

View Posts
zino zino 2 months ago
DTC Low Floats are the PinkSheet runners lately
πŸ‘οΈ0
zino zino 2 months ago
$ARTH DTC Shares Just 1.37 Million...
https://x.com/gus94202612/status/1840203380335001974
πŸ‘οΈ0
moneymaker290 moneymaker290 4 months ago
Excellent question
πŸ‘οΈ0
ANTI-BAGHOLDER ANTI-BAGHOLDER 5 months ago
What happened to going onto Nasdaq?
πŸ‘οΈ0
moneymaker290 moneymaker290 5 months ago
Anyone know what these filings r for??
πŸ‘οΈ0
Snowy_Owl Snowy_Owl 7 months ago
I'm old enough to remember when an announcement like this excited me.

Arch Therapeutics will present AC5 again at the spring Symposium on Advanced Wound Care on May 14-18. CEO Terry Norchi said: β€œPrior presentations at SAWC included a case of limb salvage in a 32 year-old patient with a necrotic spider-bite; management of post-Mohs surgery wounds; and treatment of recalcitrant wounds that previously failed to respond to other modalities. Clinicians manage a broad array of acute and chronic challenging wounds, often in patients with concurrent medical problems that interfere with healing.”
πŸ‘οΈ0
blackngold63 blackngold63 9 months ago
The float is over a million shares and only $1,373 worth of stock changed hands today.
Less than the price of one of Norchi's suits. Amazing.
πŸ‘οΈ0
moneymaker290 moneymaker290 9 months ago
Latest report,,,TOTAL REVENUE for 2023 was $45,800 or $3,800 per month. Let me repeat,,total REVENUE, $45,800 for the YEAR....how can this guy, Terry not end up is Prison,,,,how can anyone continue to loan him money...
πŸ‘οΈ0
moneymaker290 moneymaker290 10 months ago
That was the longest report I have ever read...talked 95% about years past...I never did see sales...???
πŸ‘οΈ0
moneymaker290 moneymaker290 10 months ago
Unfortunately, will go towards zero....Terry has made himself a great living for years, by milking this company
πŸ‘οΈ0
Snowy_Owl Snowy_Owl 11 months ago
I wonder if December Medicare/Medicaid sales dropped.

If I’m wrong please correct me, if ARTH can’t hold $4 isn’t the up listing off the table?
πŸ‘οΈ0
SriMaharaj SriMaharaj 11 months ago
It will continue to go up from here with anticipation of very good news.
πŸ‘οΈ0
Long Duk Dong Long Duk Dong 11 months ago
Nice rebound today, still has legs!
πŸ‘οΈ0
moneymaker290 moneymaker290 12 months ago
He sees the writing on the wall...this company will be dark soon. I'm sad to say...Poorly run for years, but CEO has made out quite well...
πŸ‘οΈ0
Snowy_Owl Snowy_Owl 12 months ago
VP of Sales, Dan Yrigoyen, resigned. He was expensive. The position did not seem to be a good fit.

I have no idea if this influenced the most recent drop in share price.
πŸ‘οΈ0
moneymaker290 moneymaker290 12 months ago
This POS is unfortunately showing its true colors..
πŸ‘οΈ0
Long Duk Dong Long Duk Dong 12 months ago
SP getting killed today!
πŸ‘οΈ0
Snowy_Owl Snowy_Owl 12 months ago
"Once it cross 11 then it will move fast."

It's more important to me how far it will move rather than how fast. Factoring in the most recent 1-for-200 reverse stock split the share price has what I think is an unfeasibly long row to hoe before I'm close to breaking even.
πŸ‘οΈ0
SriMaharaj SriMaharaj 12 months ago
Once it cross 11 then it will move fast. We should be hearing soon on moving stock to upper stock exchange soon.
πŸ‘οΈ0
SriMaharaj SriMaharaj 12 months ago
Going up. Huge bid. People want to get in before it goes on Nasdaq.
👍️ 1
SriMaharaj SriMaharaj 12 months ago
Wow. 12K+ volume in 5 minutes of opening. Selling done. Time to buy and take it to next high level.
πŸ‘οΈ0
SriMaharaj SriMaharaj 12 months ago
It did hold 10 today. This tells me that it will be 20+ tomorrow.
πŸ‘οΈ0
JDT72 JDT72 12 months ago
That is my hope for sure, today was wild and hard to hold through that run.
πŸ‘οΈ0
SriMaharaj SriMaharaj 12 months ago
They are going on Nasdaq in Jan 2024. This could be the reason they asked for advance. I believe float is locked and going to fly to the moon before goes into Nasdaq.
πŸ‘οΈ0
JDT72 JDT72 12 months ago
New to this site, started following ARTH based on Zacks ranking them as a Strong Buy and their top scoring stock for their combined ranking of value/growth/momentum. I am a bit concerned by the history of them and the recent $250K Shareholders Advance taken on 11/29.
πŸ‘οΈ0
SriMaharaj SriMaharaj 12 months ago
wow. With only 100K it's going to 100%+. What will happen if this has 500K volume. I believe it will reach $100 with that volume. No shares available.
πŸ‘οΈ0
Long Duk Dong Long Duk Dong 12 months ago
Another beauty day for ARTH!
πŸ‘οΈ0
TFWG TFWG 12 months ago
Deleted
πŸ‘οΈ0
TFWG TFWG 12 months ago
Searching and seaching for one simple answer: WHAT THE HELL IS GOING ONE?????
πŸ‘οΈ0
SriMaharaj SriMaharaj 1 year ago
wow, second round has started. It will cross $10 this time.
πŸ‘οΈ0
Snowy_Owl Snowy_Owl 1 year ago
I think the Lazarus moment is because ARTH was given an extension until early January 2024 to up list and this may be viewed by some as a positive that will take a future reverse split off the table.

I'm not excited by the current stock price as I think it has some characteristics of a pump 'n dump.
πŸ‘οΈ0
blackngold63 blackngold63 1 year ago
Have no idea what is going on. Appears to have risen from the Dead with no news and relatively small volume.
πŸ‘οΈ0
abazaba375 abazaba375 1 year ago
Congrats
πŸ‘οΈ0
abazaba375 abazaba375 1 year ago
Yep
πŸ‘οΈ0
Long Duk Dong Long Duk Dong 1 year ago
No posts on this board for months, the pps explodes in the last weeks..... and.....Silence.
πŸ‘οΈ0
Snowy_Owl Snowy_Owl 1 year ago
Anyone else notice the share price has been .666 for some time now? Weird.
πŸ‘οΈ0
moneymaker290 moneymaker290 1 year ago
You are Correct..imho
πŸ‘οΈ0
blackngold63 blackngold63 1 year ago
This is Norchi's retirement plan.
He has screwed this up so much he knows he can never get another job in the industry so he will milk this as long as he can.
πŸ‘οΈ0
moneymaker290 moneymaker290 1 year ago
I am sad to say I've been in the stock for 8 years at least he doesn't know his butt from first base talking about Norchi... he knows how to keep the company afloat so he can get that huge paycheck every month. That's all this is about now
πŸ‘οΈ0
Snowy_Owl Snowy_Owl 1 year ago
I'm not qualified to judge the legality of Norchi's actions but I do feel I am qualified to assess this most recent action as blatantly underhanded.

"What Norchi has done and continues to do HAS to be illegal,don't u think"
πŸ‘οΈ0
moneymaker290 moneymaker290 1 year ago
What Norchi has done and continues to do HAS to be illegal,,don't u think
πŸ‘οΈ0
Snowy_Owl Snowy_Owl 1 year ago
Arch Therapeutics has been pretty much over for me for awhile now. Recent actions have eliminated any remaining doubts I may have had.

ARTH dropped 31% on Thursday 9/7/23 after a series of SEC filings. On September 1 they filed a Form 14C informing us that certain actions were taken by the written consent of the holders of a majority of the outstanding voting stock in lieu of a meeting. They increased the number of authorized shares of stock from 12,000,000 to 350,000,000 shares. Then said the Board can approve another reverse split between 1-for-1.5 and 1-for-20.

On September 6 they filed an 8-K to amend the convertible notes to extend the date of the required up list to NASDAQ from August 31 to September 30. That means another reverse split is imminent because they need a stock price over $4 to up list.

In the future, anytime I get a whiff of a stock contemplating a reverse split I am selling what I own, walking away, and never looking back.
πŸ‘οΈ0
moneymaker290 moneymaker290 1 year ago
POS keeps going down. There is no what that a crime has been committed by Norchi...personal cash reagistar
πŸ‘οΈ0
moneymaker290 moneymaker290 1 year ago
13G filed today..anyone know who this is for
πŸ‘οΈ0
Polyphemus Polyphemus 1 year ago
Currently extending maturity of financing until a new exchange listing (July). $4M market cap for the last decade. Commercial since 2019
πŸ‘οΈ0
blackngold63 blackngold63 2 years ago
All things considered, the stock price is actually holding up well.
No money coming in, no prospect of any money coming in, and yet it has been fairly stable.
I was sure it would be down to a buck by now.
πŸ‘οΈ0
moneymaker290 moneymaker290 2 years ago
This has always been just a money machine for CEO Terry N...isn't that against the law??
πŸ‘οΈ0
Polyphemus Polyphemus 2 years ago
Inventory - 88% of assets; 3-mo revenue of $16K, increase of SG&A of $43K
πŸ‘οΈ0
Snowy_Owl Snowy_Owl 2 years ago
10Q will be filed late.

β€œ PART III β€” NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Arch Therapeutics, Inc. (the β€œCompany”) is unable to file its Quarterly Report on Form 10-Q for the period ended March 31, 2023 by the prescribed due date without unreasonable effort or expense because of the circumstances described below.

β€œThe Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, cannot be filed within the prescribed time period because the Company requires additional time for compilation and review to insure adequate disclosure of certain information required to be included in the Quarterly Report on Form 10-Q, including the XBRL (eXtensible Business Reporting Language) Interactive Data Files for the financial statements and notes included in the Quarterly Report. The Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 will be filed on or before the 5th calendar day following the prescribed due date.”
πŸ‘οΈ0
Polyphemus Polyphemus 2 years ago
Waiting for revenue numbers instead of conference presentations. Expect to have major inventory write-off in the not so distant future. Exec comp will probably exceed R&D and sales expenses combined.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock